The Damage-Response Framework As a Tool for the Physician-Scientist to Understand the Pathogenesis of Infectious Diseases

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2018 Aug 21

PMID 30124977

Citations 23

Authors

Liise-Anne Pirofski

Arturo Casadevall

Affiliations

Soon will be listed here.

Abstract

The Damage-Response Framework (DRF) is a powerful tool to inform research in infectious diseases. It can integrate clinical observation with microbiology and immunology to incorporate the role of the host response into the outcome of microbial pathogenesis. Although the role that microbial factors may play in the pathogenesis of infectious diseases is well recognized, the DRF brings the indispensable role of the host response to the fore. For example, inflammation may induce microbial control, but it can also produce host damage. On the other hand, insufficient inflammation may fail to induce sufficient microbial control. Each scenario may lead to the diagnosis of an infectious disease. Given the central role that the host response plays in the pathogenesis of infectious diseases, new strategies for treatment need to consider the nature of the host response as well as microbial factors.

Citing Articles

mGem: A quarter century with the Pirofski-Casadevall damage response framework-a dynamic construct for understanding microbial pathogenesis.

Nosanchuk J mBio. 2025; 16(3):e0294524.

PMID: 39932289 PMC: 11898690. DOI: 10.1128/mbio.02945-24.

A Rose by Any Other Name: The Long Intricate History of Localized Aggressive Periodontitis.

Fine D, Schreiner H, Diehl S Pathogens. 2024; 13(10).

PMID: 39452721 PMC: 11510386. DOI: 10.3390/pathogens13100849.

The microbial damage and host response framework: lesson learned from pathogenic survival trajectories and immunoinflammatory responses of infection.

Pruksaphon K, Amsri A, Jeenkeawpieam J, Thammasit P, Nosanchuk J, Youngchim S Front Immunol. 2024; 15:1448729.

PMID: 39188728 PMC: 11345217. DOI: 10.3389/fimmu.2024.1448729.

Organ-on-chip models for infectious disease research.

Alonso-Roman R, Mosig A, Figge M, Papenfort K, Eggeling C, Schacher F Nat Microbiol. 2024; 9(4):891-904.

PMID: 38528150 DOI: 10.1038/s41564-024-01645-6.

JAK/STAT Signaling Predominates in Human and Murine Fungal Post-infectious Inflammatory Response Syndrome.

Hargarten J, Ssebambulidde K, Anjum S, Vaughan M, Xu J, Song B medRxiv. 2024; .

PMID: 38293201 PMC: 10827263. DOI: 10.1101/2024.01.18.24301483.

References

Casadevall A, Pirofski L . What Is a Host? Attributes of Individual Susceptibility. Infect Immun. 2017; 86(2). PMC: 5778373. DOI: 10.1128/IAI.00636-17. View

Loo Y, Gale Jr M . Influenza: fatal immunity and the 1918 virus. Nature. 2007; 445(7125):267-8. DOI: 10.1038/445267a. View

Omer S, Phadke V, Bednarczyk R, Chamberlain A, Brosseau J, Orenstein W . Impact of Statins on Influenza Vaccine Effectiveness Against Medically Attended Acute Respiratory Illness. J Infect Dis. 2015; 213(8):1216-23. PMC: 4799662. DOI: 10.1093/infdis/jiv457. View

McClelland E, Nicola A, Prados-Rosales R, Casadevall A . Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism. J Clin Invest. 2010; 120(4):1355-61. PMC: 2846037. DOI: 10.1172/JCI38322. View

Dunst J, Kamena F, Matuschewski K . Cytokines and Chemokines in Cerebral Malaria Pathogenesis. Front Cell Infect Microbiol. 2017; 7:324. PMC: 5517394. DOI: 10.3389/fcimb.2017.00324. View

Lang Z, Zhang L, Zhang S, Meng X, Li J, Song C . A clinicopathological study of three cases of severe acute respiratory syndrome (SARS). Pathology. 2003; 35(6):526-31. PMC: 7131316. DOI: 10.1080/00313020310001619118. View

Fedson D . Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola. Ann Transl Med. 2016; 4(21):421. PMC: 5124618. DOI: 10.21037/atm.2016.11.03. View

Kobasa D, Jones S, Shinya K, Kash J, Copps J, Ebihara H . Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature. 2007; 445(7125):319-23. DOI: 10.1038/nature05495. View

Meya D, Okurut S, Zziwa G, Rolfes M, Kelsey M, Cose S . Cellular immune activation in cerebrospinal fluid from ugandans with cryptococcal meningitis and immune reconstitution inflammatory syndrome. J Infect Dis. 2014; 211(10):1597-606. PMC: 4407762. DOI: 10.1093/infdis/jiu664. View

10.

Pirofski L, Casadevall A . What is infectiveness and how is it involved in infection and immunity?. BMC Immunol. 2015; 16:13. PMC: 4374184. DOI: 10.1186/s12865-015-0076-1. View

11.

Casadevall A, Pirofski L . What is a host? Incorporating the microbiota into the damage-response framework. Infect Immun. 2014; 83(1):2-7. PMC: 4288903. DOI: 10.1128/IAI.02627-14. View

12.

Weber S, Tian H, van Rooijen N, Pirofski L . A serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibody requires Fcγ receptor III and macrophages to mediate protection against pneumococcal pneumonia in mice. Infect Immun. 2012; 80(4):1314-22. PMC: 3318404. DOI: 10.1128/IAI.06081-11. View

13.

Yano M, Gohil S, Coleman J, Manix C, Pirofski L . Antibodies to Streptococcus pneumoniae capsular polysaccharide enhance pneumococcal quorum sensing. mBio. 2011; 2(5). PMC: 3171983. DOI: 10.1128/mBio.00176-11. View

14.

Kambugu A, Meya D, Rhein J, OBrien M, Janoff E, Ronald A . Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis. 2008; 46(11):1694-701. PMC: 2593910. DOI: 10.1086/587667. View

15.

Rana A, Ahmed M, Rub A, Akhter Y . A tug-of-war between the host and the pathogen generates strategic hotspots for the development of novel therapeutic interventions against infectious diseases. Virulence. 2015; 6(6):566-80. PMC: 4720223. DOI: 10.1080/21505594.2015.1062211. View

16.

Burns T, Abadi M, Pirofski L . Modulation of the lung inflammatory response to serotype 8 pneumococcal infection by a human immunoglobulin m monoclonal antibody to serotype 8 capsular polysaccharide. Infect Immun. 2005; 73(8):4530-8. PMC: 1201218. DOI: 10.1128/IAI.73.8.4530-4538.2005. View

17.

Fabrizio K, Groner A, Boes M, Pirofski L . A human monoclonal immunoglobulin M reduces bacteremia and inflammation in a mouse model of systemic pneumococcal infection. Clin Vaccine Immunol. 2007; 14(4):382-90. PMC: 1865609. DOI: 10.1128/CVI.00374-06. View

18.

Ferguson N, Rodriguez-Barraquer I, Dorigatti I, Mier-Y-Teran-Romero L, Laydon D, Cummings D . Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment. Science. 2016; 353(6303):1033-1036. PMC: 5268127. DOI: 10.1126/science.aaf9590. View

19.

Casadevall A, Pirofski L . Host-pathogen interactions: redefining the basic concepts of virulence and pathogenicity. Infect Immun. 1999; 67(8):3703-13. PMC: 96643. DOI: 10.1128/IAI.67.8.3703-3713.1999. View

20.

Singh N, Lortholary O, Alexander B, Gupta K, John G, Pursell K . An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis. 2005; 40(12):1756-61. DOI: 10.1086/430606. View